NASDAQ$STAA

STAAR Surgical Company · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

STAAR Surgical's Q1 2022 earnings demonstrated record net sales and ICL unit growth, driven by increased surgeon and patient awareness.

STAAR Surgical reported record first-quarter net sales of $63.2 million, a 25% increase year-over-year. ICL sales grew by 26%, with unit growth up by 29%. The company reaffirmed its fiscal year 2022 net sales outlook of approximately $295 million, representing a 28% year-over-year growth.

  • Record net sales of $63.2 million, up 25% year-over-year.
  • ICL sales of $58.7 million, up 26% year-over-year.
  • Record ICL units increased 29% year-over-year.
  • Net income was $0.19 per share, compared to $0.10 per share in the prior year quarter.

Headline financials

Total Revenue

$63.2M

Previous: $50.8M+24.5%
EPS (adj)

$0.29

Previous: $0.20+45.0%
Capital Expenditures

-$2.54M

Previous: -$2.16M-17.6%
Free Cash Flow

$7.06M

Previous: $2.83M+149.3%
Net Income

$9.6M

Previous: $4.99M+92.3%
Operating Income

$12.1M

Previous: $7.47M+62.2%
Gross Profit

$49.3M

Previous: $39.1M+25.9%
Cash & Equivalents

$193M

Previous: $162M+18.9%
Total Assets

$351M

Previous: $266M+32.1%
Stock-Based Comp

$3.89M

Previous: $3.33M+16.9%

Revenue & EPS history

STAAR Surgical · Revenue · Quarterly

$63.2M

Q1 2022+24.5%vs Q1 2021
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Forward guidance

For fiscal year 2022, the company continues to anticipate approximately $295 million in net sales, which represents year-over-year growth of 28%.

Tailwinds

  • Reaffirming annual sales outlook of approximately $295 million.
  • Strong global growth in China, Japan and India.
  • FDA approval for EVO lenses.
  • Commercialization of EVO in the U.S. is underway.
  • Shipments of EVO lenses to China remain robust.

Headwinds

  • COVID-19 lockdowns in multiple cities in China.
  • Global economic conditions
  • Impact of the COVID-19 pandemic on markets
  • International trade disputes
  • Willingness of surgeons and patients to adopt new products

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

+2.4%

Avg return

Earnings day

+1.9%

Avg return

5 days after

+3.5%

Avg return

30 days after

50%

30 / 60 earnings

Positive

+29.0%

Q1 2018

Best reaction

-24.7%

Q4 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+4.3%+14.5%+0.6%
Q4 2025-1.4%-3.2%+6.8%
Q3 2025-0.3%-4.9%-0.2%
Q1 2025+0.2%-2.3%-8.1%
Q4 2024-24.7%-29.8%-22.1%
Q3 2024-4.3%-3.8%-3.9%
Q2 2024+6.5%+1.7%-17.9%
Q1 2024-10.8%-7.9%-12.0%
Q4 2023+6.6%+8.6%+22.9%
Q3 2023-13.9%-17.5%-21.1%
Q2 2023-10.5%-11.6%-18.4%
Q1 2023-5.8%-1.5%-15.9%
Q4 2022-12.7%-18.4%-9.6%
Q3 2022-18.9%-20.0%-14.1%
Q2 2022+23.1%+26.6%+16.8%
Q1 2022+1.9%-9.3%+7.6%
Q4 2021+13.1%+20.4%+10.7%
Q3 2021-1.5%-1.3%-24.8%
Q2 2021+21.3%+19.4%+22.4%
Q1 2021+8.6%-8.6%+12.6%
Q4 2020-4.3%-4.1%-9.7%
Q3 2020+2.4%+14.8%+7.0%
Q2 2020-6.8%-14.2%-16.7%
Q1 2020-0.5%+3.8%+14.8%
Q4 2019+2.0%+4.1%+1.9%
Q3 2019+14.6%+22.1%+28.8%
Q2 2019+14.9%+5.9%-0.6%
Q1 2019-13.3%-16.8%-28.7%
Q4 2018-0.6%-1.2%+2.7%
Q3 2018+10.6%+13.9%-1.2%
Q2 2018+25.6%+29.3%+54.6%
Q1 2018+29.0%+38.1%+84.8%
Q4 2017-9.1%-8.2%-7.2%
Q3 2017+12.0%+10.5%+17.0%
Q2 2017-1.4%-3.3%+11.6%
Q1 2017-2.9%-3.3%-10.0%
Q4 2016+1.5%-2.4%-4.4%
Q3 2016+9.8%+11.6%+28.0%
Q2 2016+19.9%+21.5%+30.4%
Q1 2016-22.4%
Q4 2015+17.1%
Q3 2015+13.0%
Q2 2015+1.2%
Q1 2015-6.0%
Q4 2013+10.1%
Q3 2013-3.6%
Q2 2013+18.6%
Q1 2013+20.8%
Q4 2012-5.6%
Q3 2012+7.5%
Q2 2012+26.3%
Q1 2011-10.1%
Q1 2012-0.7%
Q4 2011-0.8%
Q1 2009-0.8%
Q3 2010+7.7%
Q3 2011+7.7%
Q4 2010-6.7%
Q2 2010-6.7%
Q2 2011-6.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro